Log in
FREE 15-Day Trial
Intelligent Investor
Intelligent Investor
  1. Home
  2. Research & Advice
  3. Research Tools
  4. Shares
  5. Firebrick Pharma Limited (FRE)
  6. Company Announcements

Firebrick Pharma Limited (ASX: FRE) - Announcements

Current share price for FRE : $0.065 0.003 (4.84%)

ASX company news and announcements for Firebrick Pharma Limited (FRE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Firebrick Pharma Limited (FRE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Firebrick Pharma Limited (FRE), please use our Company Announcements tool to search across all ASX-listed companies.

Intelligent Investor free trial for buy hold sell stock recommendations

Latest company announcements for Firebrick Pharma Limited (FRE)

Search all Announcements
Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg		 Gain/Loss
$12 Update on Nasodine Trial and Forward Plans 3 Oct 2023 9:11AM $0.050 $0.065 $0.068 risen by 30%
$12 Notice of AGM and Closing Date for Director Nominations 18 Sep 2023 11:45AM $0.062 $0.065 $0.068 risen by 5.69%
$12 Phase 3 Common Cold Trial Results 13 Sep 2023 9:42AM $0.330 $0.065 $0.068 fallen by 80.30%
$12 Trading Halt 11 Sep 2023 9:37AM $0.330 $0.065 $0.068 fallen by 80.30%
$12 Appendix 4G 29 Aug 2023 5:48PM $0.285 $0.065 $0.068 fallen by 77.19%
$12 Corporate Governance Statement 29 Aug 2023 5:46PM $0.285 $0.065 $0.068 fallen by 77.19%
$12 Appendix 4E & Annual Report FY23 29 Aug 2023 5:45PM $0.285 $0.065 $0.068 fallen by 77.19%
$12 Response to ASX Price and Volume Query 28 Aug 2023 1:26PM $0.335 $0.065 $0.068 fallen by 80.60%
$12 Firebrick Phase 3 Trial Closes with 500 Subjects 9 Aug 2023 9:04AM $0.180 $0.065 $0.068 fallen by 63.89%
$12 Firebrick Covid-19 Trial Achieves Primary Endpoint 7 Aug 2023 8:16AM $0.185 $0.065 $0.068 fallen by 64.86%
$12 Update on Nasodine Phase 2 Study 1 Aug 2023 5:39PM $0.180 $0.065 $0.068 fallen by 63.89%
$12 June 2023 Quarterly Activity Report & Appendix 4C 27 Jul 2023 8:22AM $0.200 $0.065 $0.068 fallen by 67.50%
$12 Firebrick Update on AAT Process 20 Jul 2023 8:24AM $0.190 $0.065 $0.068 fallen by 65.79%
$12 Firebrick Update on Phase 2 Trial Results 12 Jul 2023 5:04PM $0.200 $0.065 $0.068 fallen by 67.50%
$12 Firebrick Update on AAT Schedule 29 Jun 2023 4:23PM $0.150 $0.065 $0.068 fallen by 56.67%
$12 Cleansing Notice 21 Jun 2023 2:38PM $0.160 $0.065 $0.068 fallen by 59.38%
$12 Change of Director's Interest Notice - Stephen Goodall 21 Jun 2023 2:36PM $0.160 $0.065 $0.068 fallen by 59.38%
$12 Change of Director's Interest Notice - Peter Molloy 21 Jun 2023 2:35PM $0.160 $0.065 $0.068 fallen by 59.38%
$12 Application for quotation of securities - FRE 21 Jun 2023 2:32PM $0.160 $0.065 $0.068 fallen by 59.38%
$12 Results of General Meeting 20 Jun 2023 11:28AM $0.155 $0.065 $0.068 fallen by 58.06%
$12 Firebrick Pharma Investor Update on Key Projects 20 Jun 2023 8:22AM $0.155 $0.065 $0.068 fallen by 58.06%
$12 Notification of cessation of securities - FRE 16 Jun 2023 8:24AM $0.155 $0.065 $0.068 fallen by 58.06%
$12 Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment 31 May 2023 9:01AM $0.175 $0.065 $0.068 fallen by 62.86%
$12 Update on Nasodine AAT Appeal Timetable 29 May 2023 6:10PM $0.165 $0.065 $0.068 fallen by 60.61%
$12 Letter to Shareholders & Notice of GM & Proxy Form 15 May 2023 12:33PM $0.190 $0.065 $0.068 fallen by 65.79%

26 - 50 of 328 results

Page 2 of 14

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.